First LC-MS/MS electrospray ionization validated method for the quantification of perindopril and its metabolite perindoprilat in human plasma and its application to bioequivalence study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 837, Issue 1-2, 2006, Pages 92-100

  Jain, Deepak S ^a,b   Subbaiah, Gunta ^b   Sanyal, Mallika ^c   Pande, Umesh C ^a   Shrivastav, Pranav ^a  

^a GUJARAT UNIVERSITY   (India)

^b Torrent Pharmaceuticals Ltd   (India)

^c ST XAVIER S COLLEGE   (India)

Author keywords

Human plasma; LC MS MS; Perindopril; Perindoprilat; SRM

Indexed keywords

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IONIZATION; MASS SPECTROMETRY; SENSITIVITY ANALYSIS; SOLVENT EXTRACTION;

HUMAN PLASMA; LC-MS/MS; PERINDOPRIL; PERINDOPRILAT; SRM;

ENZYME INHIBITION;

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; PERINDOPRIL; PERINDOPRILAT; PHOSPHORIC ACID; RAMIPRIL;

ACCURACY; ARTICLE; BIOEQUIVALENCE; DRUG BLOOD LEVEL; DRUG ISOLATION; DRUG RETENTION; ELECTROSPRAY MASS SPECTROMETRY; ELUTION; HUMAN; HYDROPHILICITY; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; INDOLES; PERINDOPRIL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; THERAPEUTIC EQUIVALENCY;

EID: 33646890876     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2006.04.008     Document Type: Article

References (13)

1. Burke M.J., and Preskorn S.H. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: Physicians' Drug References. 58th ed. (2004), Medical Economic Company, Oradell, NJ 3163
2. Erk N. J. Pharm. Biomed. Anal. 26 (2001) 43
3. Gumieniczek A., and Hopkala H. Chem. Anal. 43 (1998) 951
4. Sereda K.M., Hardman T.C., Dilloway M.R., and Lant A.F. Anal. Proc. (London) 30 (1993) 371
5. Doucet L., De Verac B., Delaage M., Cailla C., Berheim C., and Devissaguet M. J. Pharm. Sci. 79 (1990) 741
6. Lin S.J., Wu H.L., Chem S.H., and Wen Y.H. Anal. Lett. 29 (1996) 1751
7. Abdellatef E.H., Ayad M.M., and Taha A.E. J. Pharm. Biomed. Anal. 18 (1999) 1021
8. Abdellatef E.H., Ragab H.G., and Baraka M.M. J. Pharm. Sci. 7 (1998) 59
9. Hillaert S., and Van den Bossche W. J. Pharm. Biomed. Anal. 25 (2001) 775
10. Rahman N., Anwar N., and Kashif M. Chem. Pharm. Bull. (Tokyo) 54 (2006) 33
11. Tsaconas C., Devissaguet M., and Padieu P. J. Chromatogr. 488 (1989) 249
12. Guidance for Industry: Bioanalytical Method validation, U.S. Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM), May 2001.
13. FDA Guidance for Industry: Bioavailability Studies for Orally Administered Drug-Products-General Considerations, U.S. Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), 2000.